We are currently progressing a diversified portfolio of 18 programs, initially focused on genetic diseases. The “immediate” category includes diseases with a fast, direct path to treating patients, and the “differentiation” category includes diseases with high unmet need not currently addressable using other gene-editing approaches. Over time, we intend to maximize Prime Editing’s broad therapeutic potential and go beyond the genetic diseases in our initial pipeline, potentially into cell therapies, oncology, immunology, infectious diseases, xenotransplantation, and targeting genetic risk factors in common diseases. Our initial 18 programs are outlined below.
prime medicine pipeline
differentiation: repeat expansion diseases
*Pipeline reflects the current development stage and will be updated quarterly